1. Home
  2. IGI vs SPRO Comparison

IGI vs SPRO Comparison

Compare IGI & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IGI
  • SPRO
  • Stock Information
  • Founded
  • IGI 2009
  • SPRO 2013
  • Country
  • IGI United States
  • SPRO United States
  • Employees
  • IGI N/A
  • SPRO N/A
  • Industry
  • IGI Investment Managers
  • SPRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • IGI Finance
  • SPRO Health Care
  • Exchange
  • IGI Nasdaq
  • SPRO Nasdaq
  • Market Cap
  • IGI 102.0M
  • SPRO 110.9M
  • IPO Year
  • IGI N/A
  • SPRO 2017
  • Fundamental
  • Price
  • IGI $16.72
  • SPRO $2.05
  • Analyst Decision
  • IGI
  • SPRO Buy
  • Analyst Count
  • IGI 0
  • SPRO 4
  • Target Price
  • IGI N/A
  • SPRO $5.00
  • AVG Volume (30 Days)
  • IGI 33.9K
  • SPRO 299.8K
  • Earning Date
  • IGI 01-01-0001
  • SPRO 11-13-2025
  • Dividend Yield
  • IGI 4.79%
  • SPRO N/A
  • EPS Growth
  • IGI N/A
  • SPRO N/A
  • EPS
  • IGI N/A
  • SPRO N/A
  • Revenue
  • IGI N/A
  • SPRO $48,576,000.00
  • Revenue This Year
  • IGI N/A
  • SPRO N/A
  • Revenue Next Year
  • IGI N/A
  • SPRO N/A
  • P/E Ratio
  • IGI N/A
  • SPRO N/A
  • Revenue Growth
  • IGI N/A
  • SPRO N/A
  • 52 Week Low
  • IGI $15.13
  • SPRO $0.51
  • 52 Week High
  • IGI $17.79
  • SPRO $3.22
  • Technical
  • Relative Strength Index (RSI)
  • IGI 48.79
  • SPRO 55.45
  • Support Level
  • IGI $16.64
  • SPRO $1.84
  • Resistance Level
  • IGI $17.09
  • SPRO $2.05
  • Average True Range (ATR)
  • IGI 0.13
  • SPRO 0.08
  • MACD
  • IGI -0.03
  • SPRO 0.02
  • Stochastic Oscillator
  • IGI 27.45
  • SPRO 85.19

About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.

Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: